Combination treatment for early-stage esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called adebrelimab (an immunotherapy) combined with chemotherapy, endoscopy, and radiation for people with early-stage esophageal cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer without needing surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with squamous cell cancer in the middle part of your esophagus (the tube that carries food).
- Your cancer is at an early stage (T1b-2N0M0) and has not spread to lymph nodes or other organs.
- You cannot have surgery to remove the cancer, or you choose not to have surgery.
- You have not had any previous treatment for this cancer, such as chemotherapy, radiation, or surgery.
- You are generally well enough to carry out daily activities (performance status 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug called adebrelimab before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for people with locally advanced disease.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
Hear when a new Resectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.